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Abstract The nerve growth factor receptor, TrkA, is essential
for the survival and differentiation of neurons in the central and
peripheral nervous systems. To understand the molecular
principles underlying this differentiation step, we employed a
yeast two-hybrid screening protocol using human TrkA as bait.
We isolated c-Abl as a TrkA-interacting protein, in addition to
known proteins such as phospholipase CQ and SH2-B. This
interaction was confirmed by an in vitro binding assay using
glutathione S-tranferase^Abl fusion protein. Furthermore, we
show here that c-Abl binds to phosphotyrosine residue(s) in the
kinase activation loop of TrkA.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Nerve growth factor (NGF) is a member of the family of
neurotrophins and essential for the survival and di¡erentia-
tion of neurons in the central and peripheral nervous systems
[1]. The binding of NGF to its receptor TrkA causes dimer-
ization and activation of the receptor-associated tyrosine ki-
nase leading to autophosphorylation of the cytoplasmic do-
main at multiple tyrosine residues. The newly formed
phosphotyrosines constitute binding sites for Src homology
2 (SH2) domain- or phosphotyrosine binding (PTB) do-
main-containing cytoplasmic proteins which are thought to
participate in the control of mitogenic or di¡erentiation path-
ways, cell metabolism and/or cell morphology [2].
Autophosphorylation sites of human TrkA include the ty-
rosine residues Y670, Y674 and Y675, which are located with-
in the activation loop of the tyrosine kinase domain and two
tyrosine residues, Y490 and Y785, that lie outside of the ki-
nase domain. The latter two tyrosine-residues provide binding
sites for Shc and PLCQ, respectively [3,4]. In addition to these
two proteins, the TrkA tyrosine kinase was reported to inter-
act with several SH2 or PTB domain-containing proteins,
such as Crk [5], SH2-B [6] and SNT/FRS-2 [7,8]. Activation
of these signaling molecules culminates in downstream events
involved in the promotion and maintenance of neuronal sur-
vival and di¡erentiation. Shc and PLCQ are essential TrkA
e¡ector molecules. The integrity of both binding sites is re-
quired for the NGF induction of Ras-MAP kinase (MAPK)
signaling and morphological di¡erentiation of PC12 cells
[3,9]. The other e¡ector molecule, SH2-B, binds to Grb2
and may also mediate the Ras/MAPK pathway [6]. The asso-
ciation of TrkA with SH2-B plays a role for TrkA-mediated
sympathetic neuron development [6] and PC12 cell di¡erentia-
tion [10].
To understand the molecular mechanisms of the TrkA-
mediated di¡erentiation pathways, we employed a yeast two-
hybrid screening protocol based on the tyrosine-phos-
phorylated cytoplasmic domain of human TrkA as bait. We
isolated c-Abl as a TrkA-interacting protein in addition to
known proteins such as PLCQ and SH2-B. Furthermore, we
show here that c-Abl binds to phosphotyrosine residue(s) in
the kinase activation loop.
2. Materials and methods
2.1. Plasmid constructions and yeast two-hybrid screening
For expression of the cytoplasmic domains of wild-type (wt) and
mutant TrkA and c-Fms as LexA-fusions, corresponding fusion genes
were generated in pBTM116 and transformed into yeast strain L40 or
YRN974 [11,12]. A single colony, selected for expression of the LexA^
TrkA fusion-protein, was tested for TrkA autophosphorylation and
used for transformation with a VP16 cDNA library derived from a
10^11 day mouse embryo [12^14]. GST^Abl, GST^SH2-B, GST^
PLCQ and GST^TrkA fusion proteins were generated in the pGex
system (Pharmacia, Freiburg, Germany).
2.2. Binding assay using the two-hybrid system
The qualitative and quantitative evaluations of various two-hybrid
protein/protein interactions were described previously [11].
2.3. Cells and antibodies
NIH3T3 cells expressing the human TrkA gene (NIH3T3(TrkA))
were grown in Dulbecco’s modi¢ed Eagle’s medium supplemented
with 10% FCS. Monoclonal antibody against phosphotyrosine
(4G10) and polyclonal antibodies against PLCQ and TrkA were
from Upstate Biotechnology Incorporated (Lake Placid, NY, USA)
or from Santa Cruz Biotechnology (Santa Cruz, CA, USA), respec-
tively.
2.4. Tyrosine kinase assays, immunoblotting
For tyrosine kinase assays, TrkA-speci¢c immune complexes were
incubated for 30 min at room temperature with 10 WCi of [Q-32P]ATP
(Amersham Buchler, Braunschweig, Germany) in the presence of
10 mM MnCl2 and analyzed by SDS^PAGE. For the identi¢cation
of proteins by immunoblotting, proteins were transferred onto PRO-
TRAN nitrocellulose sheets (Schleicher and Schuell, Dassel, Ger-
many) by a semi-dry blotting technique. Bound antibody was visual-
ized by incubation of blots in 3 ml of 20 mM Tris^HCl, pH 7.6,
containing 137 mM NaCl and 2 WCi of 125I-labeled anti-species-
speci¢c immunoglobulin G (ICN, Eschwege, Germany). Bound radio-
activity was quanti¢ed with a model BAS1500 bio-imaging analyzer
(Fuji Photo Film Co., Kanagawa, Japan).
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2.5. In vitro transcription/translation
In vitro transcription/translation was performed using TNT
coupled reticulocyte lysate systems (Promega, Madison, WI, USA).
2.6. GST-binding assay
Strain TKX-1 (TKX, Stratagene, La Jolla, CA, USA) was used for
the isolation of phosphorylated GST^TrkA fusion proteins.
Phosphorylated GST-fusion proteins were produced as recommended
by the manufacturer [15]. The corresponding unphosphorylated mo-
lecular species were isolated from Escherichia coli strains DH5K or
BL21(DE3)-pT-Trx (Trx) [16]. Puri¢ed GST-fusion proteins were
bound for 1 h at 4‡C to glutathione (GT) agarose beads (40 Wl slurry;
Pharmacia) suspended in binding bu¡er (50 mM HEPES, pH 7.5,
150 mM NaCl, 0.01% Triton X-100, 1% Trasylol and 400 WM sodium
orthovanadate). Precharged beads were incubated overnight at 4‡C
with 32P-labeled TrkA, as generated by in vitro autophosphorylation,
or with 35S-labeled c-Abl(SH2) as generated by in vitro transcription/
translation in a total volume of 2 ml of binding bu¡er. Beads were
washed ¢ve times with binding bu¡er and pellets were analyzed by
SDS^PAGE.
3. Results and discussion
3.1. Isolation of c-Abl, SH2-B and PLCQ by yeast two-hybrid
screening
To identify proteins which speci¢cally interact with the cy-
toplasmic domain of the TrkA, we screened a mouse embryo
cDNA library using a yeast two-hybrid system [13,17]. The
bait consisted of the cytoplasmic domain of human TrkA
fused to the C terminus of the DNA-binding and dimerization
domain of LexA. Upon expression in yeast cells, dimerization
leads to interchain tyrosine phosphorylation of the two TrkA
receptor segments [14]. Screening of a cDNA library yielded
altogether 52 cDNA clones of various length falling into four
classes each of which encoded a di¡erent protein. Three of
these classes encoded the previously identi¢ed SH2 domain
containing proteins such as PLCQ, c-Abl and SH2-B (Fig.
1). In addition, we have isolated a novel binding partner,
TR17, however, the biological signi¢cance of this protein re-
mains to be studied. To our surprize, about 50% of cDNA
encoded various sizes of c-Abl, all of which contain the c-Abl^
SH2 domain (Fig. 1).
3.2. Autophosphorylated TrkA binds to GST^Abl fusion
protein
We next wanted to con¢rm the interaction of these two
proteins using GST^Abl (SH2 domain)-fusion protein. The
ligand, 32P-labeled TrkA polypeptide, was generated by in
vitro autophosphorylation and was isolated from immuno-
complexes by boiling in the presence of 1% SDS. Aliquots
of the TrkA preparation were diluted with binding bu¡er
and incubated with agarose beads that carried the GST fusion
proteins. Bound material was analyzed by SDS^PAGE and
autoradiography. As shown in Fig. 2, GST^Abl bound the
TrkA rather stronger than GST^PLCQ, but no binding was
observed with GST alone. However, we could not detect any
signi¢cant association of TrkA and endogenous c-Abl by co-
immunoprecipitation from PC12 cells as well as NIH3T3-
(TrkA) in the absence or the presence of NGF, suggesting
this interaction in vivo is rather weak or very transient.
3.3. TrkA binds directly to PLCQ, Abl, and Shc but not to Crk
To further analyze the TrkA/substrates interaction with
other binding candidates such as the p85 subunit of PI-3P
kinase or Crk, we employed the yeast two-hybrid protocol
Fig. 1. Isolation of the SH2 domains of c-Abl, PLCQ and SH2-B as binding partners of TrkA tyrosine kinase. Schematic drawing of c-Abl,
PLCQ and SH2-B. The various sizes of cDNAs encoding c-Abl, PLCQ and SH2-B obtained by the two-hybrid screening are presented as bars.
PH: Pleckstrin homology domain; SH2: Src homology 2 domain; SH3: Src homology 3 domain.
Fig. 2. GST^Abl (SH2) fusion protein binds to the tyrosine
phosphorylated TrkA. Precharged beads with puri¢ed GST-fusion
proteins were incubated overnight at 4‡C with 32P-labeled TrkA
(32P-TrkA), as generated by in vitro autophosphorylation. Following
washing, bound protein was analyzed by SDS^PAGE (A). As a
control, aliquots were analyzed by SDS^PAGE and stained with
Coomassie brilliant blue (B).
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using strain YRN974 containing a chromosomally integrated
LexA-Operator-GFP cassette. As a control, we included c-
Fms as bait [11,12]. Western blotting with anti-phosphotyro-
sine antibody clearly demonstrated that c-Fms as well as
TrkA moieties were phosphorylated on tyrosine in the yeast
two-hybrid assay (data not shown). As expected, Shc, PLCQ,
SH2-B and c-Abl bind to TrkA, however, no association
could be demonstrated between TrkA and the SH2 domain
of p85 subunit of PI-3P kinase and also Crk which associated
with c-Fms in this system (Fig. 3), suggesting these proteins
may form a complex with TrkA but do not associate directly
(Fig. 3). It has been reported that NGF induces the complex
formation of TrkA with Crk [5]. Hence, Crk may interact with
TrkA via other binding proteins such as FRS-2 [8] or c-Abl
[18].
3.4. Abl binds to the phosphorylated activation loop of TrkA
To study binding properties of the SH2 domain of Abl to
TrkA, similar binding analyses were performed again using
the yeast two-hybrid protocol with a series of TrkA mutants.
We determined whether binding required the presence of ac-
tivated TrkA molecules. As a control, we therefore included a
kinase-inactive TrkA-molecule in which the ATP binding site
K538 was replaced by a methionine residue (K538M). Asso-
ciation of TrkA with Abl was observed in kinase active TrkA
exclusively (Fig. 4A). In addition, we generated several TrkA
mutants including D668V-, Y490F-, Y785F- and its double
mutant TrkAYY490/785FF. In agreement with previous
data [3,4], replacement of Y490 or Y785 abolished the binding
of Shc or PLCQ, respectively (Fig. 4A). All tyrosine-mutants,
however, bind to c-Abl and SH2-B equally well (Fig. 4A),
indicating that one of the Abl or SH2-B binding site(s) is
di¡erent from these residues. SH2-B was found to associate
with a TrkA mutant lacking all tyrosines except the three
phosphotyrosine residues within the activation loop of the
kinase domain, suggesting these core tyrosines in the activa-
tion loop may provide the binding site for SH2-B [6]. Since
TrkA mutants lacking tyrosine residues within the activation
loop are de¢cient in kinase activity, we generated tyrosine
phosphorylated GST^TrkA (amino acid number: 667^686)
fusion protein which contains three tyrosines, Y670, Y674
and Y675, within the activation loop. As a control, we gen-
erated the GST^TrkA (749^790) which contains the PLCQ
binding site, Y785. Both fusion proteins were phosphorylated
on tyrosine in the bacteria strain TKX (Fig. 4C). In agree-
ment with previous data (Fig. 4A), only tyrosine phosphory-
lated GST^TrkA (749^790) associated with PLCQ (Fig. 4C).
Interestingly, the SH2 domain of c-Abl binds to only tyrosine
phosphorylated GST^TrkA (667^686) (Fig. 4C), indicating
that at least one of the core tyrosine residues in the activation
loop provides the binding site for c-Abl. Can a core phospho-
tyrosine be the binding site for its substrate in vivo? The
members of the Trk-family and insulin receptor (IR)-family
contain three tyrosine residues in the activation loop, all of
which are phosphorylated [3,19^21]. Among these tyrosine
residues, only the second tyrosine residue is the positional
equivalent of core tyrosine residue in other receptor tyrosine
kinases, such as the platelet-derived growth factor receptor, c-
Fms, c-Kit, or the epidermal growth factor receptor. It has
been shown that phosphotyrosine residues of IR in the acti-
vation loop bind to the SH2 domain of tyrosine phosphatase,
SHP-2 [22] and the PTB domain of insulin receptor substrate-
2 [23], suggesting the activation loop of this type of receptor
provides the binding site for its substrate. These core tyrosine
residues in the activation loop are phosphorylated prior to
Y490 and Y785 upon stimulation with NGF [24]. Therefore,
we asked next whether the binding of c-Abl modulates the
tyrosine kinase activity of TrkA. In vitro autokinase reaction
of TrkA in the presence or absence of the SH2 domain of c-
Abl as well as SH2-B did not in£uence the degree of auto-
phosphorylation of TrkA (data not shown). However, we
cannot rule out that the binding of substrates at the activation
loop of tyrosine kinase has an in£uence on phosphorylation
of other sites in vivo.
Furthermore, we found that the replacement of conserved
D668 into the V in the kinase activation loop strongly reduced
the association of Abl, Shc, SH2-B and PLCQ (Fig. 4A), sug-
gesting that tyrosine kinase activity was impaired by this re-
placement. This ¢nding is di¡erent from other receptors such
as c-Met, c-Fms or c-Kit. The mutation at the corresponding
D was originally found in the c-Kit mutant that is expressed
in mastocytoma [25]. This mutation causes the permanent
activation of c-Kit tyrosine kinase, and also in the yeast
two-hybrid system c-Kit D816V mutant was highly activated
[12,26]. Except for TrkA tyrosine kinase, other types of re-
ceptor tyrosine kinases, such as c-Fms [27], c-Met [28] and c-
Ron [29], were also activated by the corresponding point mu-
tation. Is the structure of TrkA activation loop di¡erent from
Fig. 3. TrkA binds directly to PLCQ, Shc, SH2-B and c-Abl, but
not to Crk and p85 of PI-3 kinase. pBTM116 carrying cloned
cDNAs encoding the cytoplasmic domains of either TrkA (A) or c-
Fms (B) were co-transformed with pVP16 carrying the cDNA of
the SH2 domains of Crk, p85 subunit of PI-3P kinase, PLCQ, SH2-B
or c-Abl, or the PTB domain of Shc in YRN974 [11]. 10 000 cells
of four independent transformants were analyzed for £uorescence
intensity using a Becton Dickinson FACScalibur £ow cytometer.
Values represent the mean values of four independent experiments.
Rel. green £uorescence: relative green £uorescence.
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those of these receptors? Recently, Cunningham and Greene
[30] proposed a ‘switch’ model for Trk activation. These au-
thors identi¢ed residues that form speci¢c charged pairs with
each of the three TrkA activation loop phosphotyrosines.
These residues include H639 (for pY670), R676 and R680
(for pY674) and R643 and R667 (for pY675). Taken together,
the replacement of D668 may cause conformational changes
of the activation loop, modulating the multiple step-activation
of Trk tyrosine kinase.
There are several potential roles of c-Abl which may involve
the signal transduction pathways mediated by TrkA signaling.
Firstly, an anti-proliferative e¡ect of NGF was shown to be
accompanied by the accumulation of cells in the G1 phase
[31]. Here, events a¡ecting the action of G1 regulatory pro-
teins, such as c-Abl [32] may be involved. Secondly, since the
interaction of Crk and c-Abl is well documented [18], Crk
may interact with TrkA via c-Abl and be phosphorylated on
tyrosine. Thirdly, both TrkA and c-Abl play roles in the in-
tegrin mediated signal pathways. NGF stimulates the accumu-
lation of integrin at the tips of ¢lopodia in the growth cones
of sympathetic neurons [33] and it has been reported that
integrin regulates c-Abl activity and cytoplasmic-nuclear
transport [34]. Finally, recent evidence has accumulated indi-
cating that c-Abl and its related kinase, Arg, play fundamen-
tal roles in the development and function of the mammalian
central nervous system [32,35]. Furthermore, it has been well
demonstrated in the Drosophila system that the Abl tyrosine
kinase controls motor axon outgrowth [36,37]. Clearly, addi-
Fig. 4. The SH2 domain of c-Abl binds to the phosphorylated activation loop of the TrkA. A: Interaction of PLCQ, Shc, SH2-B and c-Abl
with wild-type (wt) and mutant TrkAs. The SH2 domain of PLCQ, SH2-B and c-Abl and the PTB domain of Shc were co-expressed as VP16
fusion proteins together with the wild-type and mutant LexA-TrkA fusion proteins in YRN974. Mutants carry tyrosine/phenylalanine replace-
ments as indicated. K538M: a kinase-negative TrkA mutant lacking the ATP-binding site. D668V: the conserved D668 was replaced by V. B:
Schematic drawing of the cytoplasmic domain of TrkA. PM: plasma membrane; AL: activation loop; CT: C-terminal domain. Tyrosine resi-
dues, ATP-binding site K538 and conserved D668 in the activation loop are indicated. The open box represents kinase domain. C: GST^TrkA
(667^686) containing three tyrosines, Y670, Y674 and Y675, in the activation loop binds to c-Abl. GST^TrkA (667^686), GST^TrkA (749^
790), or GST alone, were produced in bacterial strains DH5(a), BL21(DE3)-pT-Trx (Trx) or TKX to generate either non-phosphorylated or
phosphorylated TrkA-species, respectively. GST-fusion protein or GST were bound to GT-agarose beads and incubated with 35S-labeled SH2
domain of c-Abl. Bound protein was analyzed by SDS-PAGE. As a control, cell lysate obtained from PC12 was incubated with GST-fusion
proteins and bound proteins were analyzed by immunobloting using polyclonal antibody against PLCQ. To demonstrate tyrosine phosphory-
lation of TrkA (667^686) and TrkA (749^790) from strain TKX, aliquots of the same samples were analyzed by immunoblotting using an anti-
phosphotyrosine monoclonal antibody. As a control, aliquots were analyzed by SDS^PAGE and stained with Coomassie brilliant blue.
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tional experiments are required to support the potential role(s)
of c-Abl in TrkA mediated signal pathways.
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